How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?

Engert, 2016, Treatment of early-stage Hodgkin lymphoma, Semin Hematol, 53, 165, 10.1053/j.seminhematol.2016.05.004 Engert, 2010, Reduced treatment intensity in patients with early-stage Hodgkin lymphoma, N Engl J Med, 363, 640, 10.1056/NEJMoa1000067 Ng, 2002, Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger, J Clin Oncol, 20, 2101, 10.1200/JCO.2002.08.021 Brusamolino, 1994, Early-stage Hodgkin disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy, Ann Oncol, 5, 101, 10.1093/annonc/5.suppl_2.S101 Bonadonna, 2004, ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin disease: long-term results, J Clin Oncol, 22, 2835, 10.1200/JCO.2004.12.170 Engert, 2003, J Clin Oncol, 21, 3601, 10.1200/JCO.2003.03.023 Fermé, 2007, Chemotherapy plus involved-field radiation in early-stage Hodgkin disease, N Engl J Med, 357, 1916, 10.1056/NEJMoa064601 Hutchings, 2005, Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma, Ann Oncol, 16, 1160, 10.1093/annonc/mdi200 Gallamini, 2007, Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study, J Clin Oncol, 25, 3746, 10.1200/JCO.2007.11.6525 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Juweid, 2007, Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma, J Clin Oncol, 25, 571, 10.1200/JCO.2006.08.2305 Meignan, 2009, Report on the First International Workshop on Interim-PET-Scan in Lymphoma, Leuk Lymphoma, 50, 1257, 10.1080/10428190903040048 Evens, 2014, The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease, Blood, 124, 3356, 10.1182/blood-2014-05-577627 Mesguich, 2016, Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation, Br J Haematol, 175, 652, 10.1111/bjh.14292 Filippi, 2013, Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy, Leuk Lymphoma, 54, 1183, 10.3109/10428194.2012.735667 Barnes, 2011, End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin lymphoma, Ann Oncol, 22, 910, 10.1093/annonc/mdq549 Sher, 2009, Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin lymphoma: the importance of involved-field radiotherapy, Ann Oncol, 20, 1848, 10.1093/annonc/mdp071 Cerci, 2010, 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma, J Nucl Med, 51, 1337, 10.2967/jnumed.109.073197 Hutchings, 2006, FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, 107, 52, 10.1182/blood-2005-06-2252 Radford, 2015, Results of a trial of PET-directed therapy for early-stage Hodgkin lymphoma, N Engl J Med, 372, 1598, 10.1056/NEJMoa1408648 Raemaekers, 2014, Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial, J Clin Oncol, 32, 1188, 10.1200/JCO.2013.51.9298 Bakhshi, 2017, Post-treatment PET-CT rather than interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET-CT versus conventional imaging, J Nucl Med, 58, 577, 10.2967/jnumed.116.176511 Adams, 2016, Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis, Eur J Radiol, 85, 1963, 10.1016/j.ejrad.2016.08.011 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Cerci, 2010, Cost Effectiveness of positron emission tomography in patients with Hodgkin lymphoma in unconfirmed complete remission or partial remission after first-line therapy, J Clin Oncol, 28, 1415, 10.1200/JCO.2009.25.4367 Ganesan, 2015, Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin lymphoma, Ann Oncol, 26, 1170, 10.1093/annonc/mdv077 Savage, 2015, Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation, Blood, 126, 579, 10.1182/blood.V126.23.579.579 Engert, 2012, Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial, Lancet, 379, 1791, 10.1016/S0140-6736(11)61940-5 Advani, 2007, Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin disease, J Clin Oncol, 25, 3902, 10.1200/JCO.2007.11.9867 Kobe, 2014, Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma, J Clin Oncol, 32, 1776, 10.1200/JCO.2013.53.2507 Dhakal, 2009, Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin lymphoma, Int J Radiat Oncol Biol Phys, 75, 188, 10.1016/j.ijrobp.2008.10.048 von Tresckow, 2011, The role of autologous transplantation in Hodgkin lymphoma, Curr Hematol Malig Rep, 6, 172, 10.1007/s11899-011-0091-0 Linch, 1993, Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomised trial, Lancet, 341, 1051, 10.1016/0140-6736(93)92411-L Schmitz, 2002, Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomised trial, Lancet, 359, 2065, 10.1016/S0140-6736(02)08938-9 Moskowitz, 2010, Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, 116, 4934, 10.1182/blood-2010-05-282756 Eroglu, 2015, Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation, Am J Clin Oncol, 38, 68, 10.1097/COC.0b013e3182880b9f Shafer, 2010, Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin lymphoma in adolescents and young adults at a single institution, Leuk Lymphoma, 51, 664, 10.3109/10428190903580410 Poen, 1996, High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin disease: the impact of involved field radiotherapy on patterns of failure and survival, Int J Radiat Oncol Biol Phys, 36, 3, 10.1016/S0360-3016(96)00277-5 Wendland, 2006, The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease, Am J Clin Oncol, 29, 189, 10.1097/01.coc.0000209370.61355.8e Levis, 2017, Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin lymphoma with incomplete response before autologous stem cell transplantation, Clin Lymphoma Myeloma Leuk, 17, 14, 10.1016/j.clml.2016.09.008 Gentzler, 2014, F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma, Br J Haematol, 165, 793, 10.1111/bjh.12824 Jabbour, 2007, Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma, Cancer, 109, 2481, 10.1002/cncr.22714 Moskowitz, 2012, Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 119, 1665, 10.1182/blood-2011-10-388058 Sucak, 2011, Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival, Ann Hematol, 90, 1329, 10.1007/s00277-011-1209-0 Adams, 2016, Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis, Ann Hematol, 95, 695, 10.1007/s00277-016-2619-9 Okeley, 2010, Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate, Clin Cancer Res, 16, 888, 10.1158/1078-0432.CCR-09-2069 Younes, 2012, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma, J Clin Oncol, 30, 2183, 10.1200/JCO.2011.38.0410 Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [e-pub ahead of print]. J Clin Oncol http://dx.doi.org/10.1200/JCO.2016.67.3467, accessed April 8, 2017.